Onder Tonyali, Ugur Coskun, Nur Sener, Mevlude Inanc, Tulay Akman, Arife Ulas, Dogan Yazilitas, Oznur Bal, Mehmet Kucukoner, Nuriye Yildirim Ozdemir, Umut Demirci, Yusuf Gunaydin, Ramazan Yildiz, Halit Karaca, Olcun Umit Unal, Mahmut Gumus, Mustafa Benekli, Suleyman Buyukberber
BACKGROUND: The objective of this study was to identify prognostic factors affecting the recurrence-free survival (RFS) in patients who received a 52-week trastuzumab therapy for HER2-positive early stage breast cancer (EBC). PATIENTS AND METHODS: The medical records of all patients with EBC from 10 centers were analyzed. Pathologic and clinical tumor characteristics were evaluated in 424 female patients who received 52 weeks of adjuvant trastuzumab for HER2-positive EBC...
2013: Onkologie